Suppr超能文献

择期腹部手术成人应用围手术期益生菌或合生剂:随机对照试验的系统评价和荟萃分析。

Perioperative Probiotics or Synbiotics in Adults Undergoing Elective Abdominal Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

机构信息

Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, UK.

Department of Gastroenterology, Hepatology and Nutrition, Clinical Hospital Centre and School of Medicine Zagreb, Zagreb, Croatia.

出版信息

Ann Surg. 2020 Jun;271(6):1036-1047. doi: 10.1097/SLA.0000000000003581.

Abstract

OBJECTIVE

To define the impact of perioperative treatment with probiotics or synbiotics on postoperative outcome in patients undergoing abdominal surgery.

BACKGROUND

Postoperative surgical infection accounts for a third of all cases of sepsis, and is a leading cause of morbidity and mortality. Probiotics, prebiotics, and synbiotics (preparations that combine probiotics and prebiotics) are nutritional adjuncts that are emerging as novel therapeutic modalities for preventing surgical infections. However, current evidence on their effects is conflicting.

METHODS

A comprehensive search of the PubMed, Embase, and WHO Global Index Medicus electronic databases was performed to identify randomized controlled trials evaluating probiotics or synbiotics in adult patients undergoing elective colorectal, upper gastrointestinal, transplant, or hepatopancreaticobiliary surgery. Bibliographies of studies were also searched. The primary outcome measure was incidence of postoperative infectious complications. Secondary outcomes included incidence of noninfectious complications, mortality, length of hospital stay, and any treatment-related adverse events. Quantitative pooling of the data was undertaken using a random effects model.

RESULTS

A total of 34 randomized controlled trials reporting on 2723 participants were included. In the intervention arm, 1354 patients received prebiotic or symbiotic preparations, whereas 1369 patients in the control arm received placebo or standard care. Perioperative administration of either probiotics or synbiotics significantly reduced the risk of infectious complications following abdominal surgery [relative risk (RR) 0.56; 95% confidence interval (CI) 0.46-0.69; P < 0.00001, n = 2723, I = 42%]. Synbiotics showed greater effect on postoperative infections compared with probiotics alone (synbiotics RR: 0.46; 95% CI: 0.33-0.66; P < 0.0001, n = 1399, I = 53% probiotics RR: 0.65; 95% CI: 0.53-0.80; P < 0.0001, n = 1324, I = 18%). Synbiotics but not probiotics also led to a reduction in total length of stay (synbiotics weighted mean difference: -3.89; 95% CI: -6.60 to -1.18 days; P = 0.005, n = 535, I = 91% probiotics RR: -0.65; 95% CI: -2.03-0.72; P = 0.35, n = 294, I = 65%). There were no significant differences in mortality (RR: 0.98; 95% CI: 0.54-1.80; P = 0.96, n = 1729, I = 0%) or noninfectious complications between the intervention and control groups. The preparations were well tolerated with no significant adverse events reported.

CONCLUSIONS

Probiotics and synbiotics are safe and effective nutritional adjuncts in reducing postoperative infective complications in elective abdominal surgery. The treatment effects are greatest with synbiotics.

摘要

目的

明确围手术期应用益生菌或合生剂对接受腹部手术患者术后结局的影响。

背景

术后手术感染占所有脓毒症病例的三分之一,是发病率和死亡率的主要原因。益生菌、益生元和合生剂(将益生菌和益生元结合在一起的制剂)是新兴的营养辅助物,可作为预防手术感染的新治疗方法。然而,目前关于其疗效的证据相互矛盾。

方法

对 PubMed、Embase 和世界卫生组织全球医学索引电子数据库进行全面检索,以确定评价成年患者接受择期结直肠、上消化道、移植或肝胆胰手术时应用益生菌或合生剂的随机对照试验。还对研究的参考文献进行了搜索。主要结局测量指标是术后感染性并发症的发生率。次要结局包括非感染性并发症、死亡率、住院时间和任何与治疗相关的不良事件的发生率。采用随机效应模型对数据进行定量汇总。

结果

共纳入 34 项随机对照试验,涉及 2723 名参与者。在干预组中,1354 名患者接受了益生元或合生制剂治疗,而对照组 1369 名患者接受安慰剂或标准治疗。围手术期应用益生菌或合生剂可显著降低腹部手术后感染性并发症的风险[相对风险(RR)0.56;95%置信区间(CI)0.46-0.69;P<0.00001,n=2723,I=42%]。合生剂在预防术后感染方面的效果优于单纯益生菌(合生剂 RR:0.46;95% CI:0.33-0.66;P<0.0001,n=1399,I=53%;益生菌 RR:0.65;95% CI:0.53-0.80;P<0.0001,n=1324,I=18%)。合生剂还可导致总住院时间缩短(合生剂加权均数差值:-3.89;95% CI:-6.60 至-1.18 天;P=0.005,n=535,I=91%;益生菌 RR:-0.65;95% CI:-2.03-0.72;P=0.35,n=294,I=65%)。两组间死亡率(RR:0.98;95% CI:0.54-1.80;P=0.96,n=1729,I=0%)或非感染性并发症无显著差异。这些制剂耐受性良好,未报告有任何不良事件。

结论

益生菌和合生剂是安全有效的营养辅助物,可降低择期腹部手术的术后感染性并发症。合生剂的治疗效果最大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验